RMB Capital Management LLC lifted its stake in shares of Catalent, Inc. (NYSE:CTLT) by 4.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 167,814 shares of the company’s stock after purchasing an additional 7,724 shares during the quarter. RMB Capital Management LLC owned about 0.10% of Catalent worth $14,375,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors also recently made changes to their positions in CTLT. Robeco Institutional Asset Management B.V. acquired a new stake in shares of Catalent during the 2nd quarter worth approximately $175,000. New York State Teachers Retirement System increased its position in Catalent by 28.4% in the 2nd quarter. New York State Teachers Retirement System now owns 100,400 shares of the company’s stock valued at $7,359,000 after acquiring an additional 22,200 shares during the period. Oregon Public Employees Retirement Fund increased its position in Catalent by 47.7% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 86,024 shares of the company’s stock valued at $6,306,000 after acquiring an additional 27,800 shares during the period. First Trust Advisors LP increased its position in Catalent by 13.1% in the 2nd quarter. First Trust Advisors LP now owns 83,886 shares of the company’s stock valued at $6,149,000 after acquiring an additional 9,726 shares during the period. Finally, Mn Services Vermogensbeheer B.V. acquired a new stake in Catalent in the 2nd quarter valued at approximately $9,749,000. Institutional investors and hedge funds own 91.03% of the company’s stock.
Several analysts recently commented on CTLT shares. Jefferies Financial Group raised their target price on Catalent from $107.00 to $115.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. Zacks Investment Research upgraded Catalent from a “hold” rating to a “buy” rating and set a $114.00 target price on the stock in a research report on Tuesday, November 10th. Argus raised their target price on Catalent from $100.00 to $110.00 in a research report on Thursday, September 24th. Morgan Stanley lifted their price target on Catalent from $98.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, November 4th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on Catalent from $91.00 to $100.00 and gave the company a “hold” rating in a research report on Thursday, November 5th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Catalent currently has a consensus rating of “Buy” and a consensus price target of $106.44.
Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.06. The business had revenue of $845.70 million during the quarter, compared to analyst estimates of $812.87 million. Catalent had a return on equity of 14.20% and a net margin of 9.25%. The company’s revenue was up 27.2% compared to the same quarter last year. During the same period last year, the company posted $0.26 EPS. Sell-side analysts expect that Catalent, Inc. will post 2.28 EPS for the current year.
In other news, SVP Michael J. Grippo sold 1,680 shares of the firm’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $94.99, for a total value of $159,583.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO John R. Chiminski sold 182,231 shares of the firm’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $86.01, for a total value of $15,673,688.31. The disclosure for this sale can be found here. Over the last three months, insiders have sold 211,858 shares of company stock valued at $18,387,619. Corporate insiders own 1.00% of the company’s stock.
Catalent Company Profile
Catalent, Inc, together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.
Featured Article: Discover Your Risk Tolerance
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.